We are live on ! Find out more
HARP

Harpoon Therapeutics, Inc. Common Stock

Delisted

HARP was delisted on the 8th of March, 2024.

84 hedge funds and large institutions have $196M invested in Harpoon Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 28 increasing their positions, 19 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

47% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 19

1% more call options, than puts

Call options by funds: $463K | Put options by funds: $457K

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

3% less capital invested

Capital invested by funds: $203M → $196M (-$6.89M)

10% less funds holding

Funds holding: 9384 (-9)

35% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 23

Holders
84
Holders Change
-9
Holders Change %
-9.68%
% of All Funds
1.29%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
15
Increased
28
Reduced
19
Closed
23
Calls
$463K
Puts
$457K
Net Calls
+$6K
Net Calls Change
+$34K
Name Holding Trade Value Shares
Change
Change in
Stake
MB
1
MPM BioImpact
Massachusetts
$24.1M
NLVP
2
New Leaf Venture Partners
New York
$23.8M
MAM
3
MPM Asset Management
Massachusetts
$23.6M
O
4
OrbiMed
New York
$21.9M +$1.99M +29,220 +11%
LGM
5
Logos Global Management
California
$14.6M +$13.2M +193,000 New
BlackRock
6
BlackRock
New York
$12.9M -$129K -1,885 -1%
Vanguard Group
7
Vanguard Group
Pennsylvania
$9.47M -$221K -3,237 -3%
Franklin Resources
8
Franklin Resources
California
$9.15M +$548K +8,026 +7%
AG
9
Artal Group
Luxembourg
$7.55M
CS
10
Candriam SCA
Luxembourg
$6.11M +$2.18M +32,006 +65%
Point72 Asset Management
11
Point72 Asset Management
Connecticut
$4.91M +$4.44M +65,000 New
CAM
12
Cormorant Asset Management
Massachusetts
$4.08M
NCM
13
Nantahala Capital Management
Connecticut
$3.59M +$389K +5,699 +14%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$3.15M +$255K +3,736 +10%
State Street
15
State Street
Massachusetts
$2.9M +$4.37K +64 +0.2%
Jacobs Levy Equity Management
16
Jacobs Levy Equity Management
New Jersey
$2.47M +$1.64M +23,971 +275%
Marshall Wace
17
Marshall Wace
United Kingdom
$1.78M +$1.61M +23,550 New
Two Sigma Advisers
18
Two Sigma Advisers
New York
$1.77M -$974K -14,270 -38%
IBT
19
International Biotechnology Trust
United Kingdom
$1.62M
JP Morgan Chase
20
JP Morgan Chase
New York
$1.54M -$67.2K -985 -5%
Northern Trust
21
Northern Trust
Illinois
$1.44M -$46.5K -681 -3%
KCM
22
Kennedy Capital Management
Missouri
$980K +$886K +12,977 New
Federated Hermes
23
Federated Hermes
Pennsylvania
$965K -$1.5K -22 -0.2%
Two Sigma Investments
24
Two Sigma Investments
New York
$887K -$1.97M -28,903 -71%
Goldman Sachs
25
Goldman Sachs
New York
$847K +$169K +2,470 +28%

HARP Hedge Fund Activity: Q4 2021 in Review

84 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Harpoon Therapeutics, Inc. Common Stock (HARP) for Q4 2021, worth a combined $196M — down 3.4% from $203M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of HARP and 15 opened new positions — a net loss of 8 holders — while 19 trimmed existing stakes and 28 added.

The largest buyer was Logos Global Management, opening a new position worth an estimated $13.2M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $9.41M sold.

  • 84 institutional investors held Harpoon Therapeutics, Inc. Common Stock (HARP) as of Q4 2021, down from 93 in Q3 2021.
  • Funds reported $196M of Harpoon Therapeutics, Inc. Common Stock stock for Q4 2021, down 3.4% quarter-over-quarter.
  • 15 funds opened new Harpoon Therapeutics, Inc. Common Stock positions in Q4 2021 and 23 closed out, a net change of -8 holders.
  • The largest Harpoon Therapeutics, Inc. Common Stock buyer in Q4 2021 was Logos Global Management, an estimated $13.2M added.
  • The largest Harpoon Therapeutics, Inc. Common Stock seller in Q4 2021 was Avidity Partners Management, an estimated $9.41M sold.

Based on aggregated 13F filings for Q4 2021.